| Added by | llasorsa |
|---|---|
| Group name | EquipeMY |
| Item Type | Journal Article |
| Title | Stereotactic MR-Guided Radiotherapy for Pancreatic Tumors: Dosimetric Benefit of Adaptation and First Clinical Results in a Prospective Registry Study |
| Creator | Michalet et al. |
| Author | Morgan Michalet |
| Author | Karl Bordeau |
| Author | Marie Cantaloube |
| Author | Simon Valdenaire |
| Author | Pierre Debuire |
| Author | Sebastien Simeon |
| Author | Fabienne Portales |
| Author | Roxana Draghici |
| Author | Marc Ychou |
| Author | Eric Assenat |
| Author | Marie Dupuy |
| Author | Sophie Gourgou |
| Author | Pierre-Emmanuel Colombo |
| Author | Pascal Fenoglietto |
| Author | David Azria |
| Author | Olivier Riou |
| Abstract | Introduction: Stereotactic MR-guided adaptive radiotherapy (SMART) is an attractive modality of radiotherapy for pancreatic tumors. The objectives of this prospective registry study were to report the dosimetric benefits of daily adaptation of SMART and the first clinical results in pancreatic tumors. Materials and Methods: All patients treated in our center with SMART for a pancreatic tumor were included. Patients were planned for five daily-adapted fractions on consecutive days. Endpoints were acute toxicities, late toxicities, impact of adaptive treatment on target volume coverage and organs at risk (OAR) sparing, local control (LC) rate, distant metastasis-free survival (DMFS), and overall survival (OS). Results: Thirty consecutive patients were included between October 2019 and April 2021. The median dose prescription was 50 Gy. No patient presented grade > 2 acute toxicities. The most frequent grade 1-2 toxicities were asthenia (40%), abdominal pain (40%), and nausea (43%). Daily adaptation significantly improved planning target volume (PTV) and gross tumor volume (GTV) coverage and OAR sparing. With a median follow-up of 9.7 months, the median OS, 6-month OS, and 1-year OS were 14.1 months, 89% (95% CI: 70%-96%), and 75% (95% CI: 51%-88%), respectively, from SMART completion. LC at 6 months and 1 year was respectively 97% (95% CI: 79-99.5%) and 86% (95% CI: 61%-95%). There were no grade > 2 late toxicities. With a median follow-up of 10.64 months, locally advanced pancreatic cancer (LAPC) and borderline resectable pancreatic cancer (BRPC) patients (22 patients) had a median OS, 6-month OS, and 1-year OS from SMART completion of 14.1 months, 76% (95% CI: 51%-89%), and 70% (95% CI: 45%-85%), respectively. Nine patients underwent surgical resection (42.1% of patients with initial LAPC and 33.3% of patients with BRPC), with negative margins (R0). Resected patients had a significantly better OS as compared to unresected patients (p = 0.0219, hazard ratio (HR) = 5.78 (95% CI: 1.29-25.9)). Conclusion: SMART for pancreatic tumors is feasible without limiting toxicities. Daily adaptation demonstrated a benefit for tumor coverage and OAR sparing. The severity of observed acute and late toxicities was low. OS and LC rates were promising. SMART achieved a high secondary resection rate in LAPC patients. Surgery after SMART seemed to be feasible and might increase OS in these patients. |
| Publication | Frontiers in Oncology |
| Volume | 12 |
| Pages | 842402 |
| Date | 2022 |
| Journal Abbr | Front Oncol |
| Language | eng |
| DOI | 10.3389/fonc.2022.842402 |
| ISSN | 2234-943X |
| Short Title | Stereotactic MR-Guided Radiotherapy for Pancreatic Tumors |
| Library Catalog | PubMed |
| Extra | PMID: 35356227 PMCID: PMC8959839 |
| Tags | adaptive radiotherapy, borderline resectable pancreatic cancers, image guided radiotherapy (IGRT), locally advanced pancreatic cancer, pancreatic tumors, stereotactic body radiation therapy, stereotactic MR-guided adaptive radiotherapy |
| Date Added | 2022/08/30 - 16:03:31 |
| Date Modified | 2024/10/10 - 16:31:57 |
| Notes and Attachments | PubMed entry (Attachment) Texte intégral (Attachment) Texte intégral (Attachment) |
Institut de Recherche en Cancérologie de
